WO2023001045A9 - 一种外用消炎偶联化合物药物及其制法和应用 - Google Patents
一种外用消炎偶联化合物药物及其制法和应用 Download PDFInfo
- Publication number
- WO2023001045A9 WO2023001045A9 PCT/CN2022/105503 CN2022105503W WO2023001045A9 WO 2023001045 A9 WO2023001045 A9 WO 2023001045A9 CN 2022105503 W CN2022105503 W CN 2022105503W WO 2023001045 A9 WO2023001045 A9 WO 2023001045A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- mmol
- group
- pyrrolo
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 302
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000003110 anti-inflammatory effect Effects 0.000 title claims description 43
- 230000008878 coupling Effects 0.000 title claims description 12
- 238000010168 coupling process Methods 0.000 title claims description 12
- 238000005859 coupling reaction Methods 0.000 title claims description 12
- 239000003814 drug Substances 0.000 title description 13
- 229940079593 drug Drugs 0.000 title description 12
- -1 amine compound Chemical class 0.000 claims abstract description 198
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 20
- 238000006356 dehydrogenation reaction Methods 0.000 claims abstract description 12
- 238000005906 dihydroxylation reaction Methods 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 1089
- 238000006243 chemical reaction Methods 0.000 claims description 308
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 273
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical group Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 269
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 192
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 182
- 239000002904 solvent Substances 0.000 claims description 172
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 151
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 142
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims description 133
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 129
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 122
- 239000003208 petroleum Substances 0.000 claims description 91
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 49
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 45
- 239000000651 prodrug Substances 0.000 claims description 45
- 229940002612 prodrug Drugs 0.000 claims description 45
- 239000002207 metabolite Substances 0.000 claims description 43
- 239000012453 solvate Substances 0.000 claims description 43
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 36
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical group 0.000 claims description 30
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 29
- 239000004012 Tofacitinib Substances 0.000 claims description 29
- 229950000971 baricitinib Drugs 0.000 claims description 29
- 229960000215 ruxolitinib Drugs 0.000 claims description 29
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 29
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 29
- 229960001350 tofacitinib Drugs 0.000 claims description 29
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 25
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 24
- HJWLJNBZVZDLAQ-HAQNSBGRSA-N chembl2103874 Chemical compound C1C[C@@H](CS(=O)(=O)NC)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2 HJWLJNBZVZDLAQ-HAQNSBGRSA-N 0.000 claims description 23
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 22
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 claims description 21
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 18
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 18
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 18
- 229960001680 ibuprofen Drugs 0.000 claims description 17
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 claims description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 16
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 16
- 229960000991 ketoprofen Drugs 0.000 claims description 16
- 229960002009 naproxen Drugs 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 15
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims description 15
- 229960005293 etodolac Drugs 0.000 claims description 15
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 claims description 15
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 14
- 239000003054 catalyst Substances 0.000 claims description 14
- 229960001419 fenoprofen Drugs 0.000 claims description 14
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 14
- 229960002390 flurbiprofen Drugs 0.000 claims description 14
- 229960000905 indomethacin Drugs 0.000 claims description 14
- HOBFSNNENNQQIU-SNVBAGLBSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylacetic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 HOBFSNNENNQQIU-SNVBAGLBSA-N 0.000 claims description 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 13
- 125000003277 amino group Chemical group 0.000 claims description 13
- 239000000460 chlorine Substances 0.000 claims description 13
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 229960001259 diclofenac Drugs 0.000 claims description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 10
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 10
- AYDXAULLCROVIT-UHFFFAOYSA-N indobufen Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1N1C(=O)C2=CC=CC=C2C1 AYDXAULLCROVIT-UHFFFAOYSA-N 0.000 claims description 10
- 229960003464 mefenamic acid Drugs 0.000 claims description 10
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 claims description 10
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 9
- 229940126062 Compound A Drugs 0.000 claims description 9
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 238000006482 condensation reaction Methods 0.000 claims description 9
- 229960004955 oclacitinib Drugs 0.000 claims description 9
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 claims description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 239000011737 fluorine Substances 0.000 claims description 7
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 claims description 7
- 229960002905 tolfenamic acid Drugs 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 229960003422 indobufen Drugs 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 125000006823 (C1-C6) acyl group Chemical group 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical class 0.000 claims description 4
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical group N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 claims description 3
- TZIJDLHRFZUDHD-UHFFFAOYSA-N 2h-thieno[2,3-e]thiazine Chemical class C1=CNSC2=C1SC=C2 TZIJDLHRFZUDHD-UHFFFAOYSA-N 0.000 claims description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000003236 benzoyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 claims description 3
- 229910000071 diazene Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical class 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- PVNIYDCDHSFJTK-UHFFFAOYSA-N 2h-1,2-benzothiazin-4-ol Chemical compound C1=CC=C2C(O)=CNSC2=C1 PVNIYDCDHSFJTK-UHFFFAOYSA-N 0.000 claims description 2
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 claims description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical class [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- 239000007821 HATU Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 3
- JALUUBQFLPUJMY-UHFFFAOYSA-N 2-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 JALUUBQFLPUJMY-UHFFFAOYSA-N 0.000 claims 1
- DDFGTVSLZJLQEV-UHFFFAOYSA-N [C](C1CCCCC1)C1CCCCC1 Chemical compound [C](C1CCCCC1)C1CCCCC1 DDFGTVSLZJLQEV-UHFFFAOYSA-N 0.000 claims 1
- 229940060037 fluorine Drugs 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 4
- 238000013267 controlled drug release Methods 0.000 abstract 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 258
- 239000000243 solution Substances 0.000 description 167
- 239000012043 crude product Substances 0.000 description 154
- 238000010898 silica gel chromatography Methods 0.000 description 153
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 151
- 239000007787 solid Substances 0.000 description 151
- 238000005481 NMR spectroscopy Methods 0.000 description 150
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 149
- 239000012044 organic layer Substances 0.000 description 149
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 147
- 238000003786 synthesis reaction Methods 0.000 description 137
- 230000015572 biosynthetic process Effects 0.000 description 130
- 238000003756 stirring Methods 0.000 description 60
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 48
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 36
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 36
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 30
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 22
- 239000012046 mixed solvent Substances 0.000 description 21
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 20
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 description 18
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 17
- MTBCJBXNKLTBMH-OCCSQVGLSA-N C[C@H](CCN(C1)C(CC#N)=O)[C@H]1N(C)C1=NC=NC2=C1C=CN2CO Chemical compound C[C@H](CCN(C1)C(CC#N)=O)[C@H]1N(C)C1=NC=NC2=C1C=CN2CO MTBCJBXNKLTBMH-OCCSQVGLSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- VBRGCXYIDDTDFK-JOCQHMNTSA-N CNS(C[C@H](CC1)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2CO)(=O)=O Chemical compound CNS(C[C@H](CC1)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2CO)(=O)=O VBRGCXYIDDTDFK-JOCQHMNTSA-N 0.000 description 14
- 150000001335 aliphatic alkanes Chemical class 0.000 description 14
- 239000002674 ointment Substances 0.000 description 14
- 235000019260 propionic acid Nutrition 0.000 description 11
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 10
- 102000042838 JAK family Human genes 0.000 description 9
- 108091082332 JAK family Proteins 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- MROJXXOCABQVEF-UHFFFAOYSA-N Actarit Chemical compound CC(=O)NC1=CC=C(CC(O)=O)C=C1 MROJXXOCABQVEF-UHFFFAOYSA-N 0.000 description 8
- 201000004681 Psoriasis Diseases 0.000 description 8
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 8
- RDJGLLICXDHJDY-UHFFFAOYSA-N fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- WQJFIWXYPKYBTO-UHFFFAOYSA-N indole-1-acetic acid Chemical compound C1=CC=C2N(CC(=O)O)C=CC2=C1 WQJFIWXYPKYBTO-UHFFFAOYSA-N 0.000 description 8
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 7
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- BIOCOYIPJQMGTN-UHFFFAOYSA-N methyl 2-(3-benzoylphenyl)propanoate Chemical compound COC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 BIOCOYIPJQMGTN-UHFFFAOYSA-N 0.000 description 6
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 6
- VZLCVCNTTZKGRF-UHFFFAOYSA-N 1,1-dioxo-2h-thiazine-3-carboxamide Chemical compound NC(=O)C1=CC=CS(=O)(=O)N1 VZLCVCNTTZKGRF-UHFFFAOYSA-N 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- LOWWYYZBZNSPDT-ZBEGNZNMSA-N delgocitinib Chemical compound C[C@H]1CN(C(=O)CC#N)[C@@]11CN(C=2C=3C=CNC=3N=CN=2)CC1 LOWWYYZBZNSPDT-ZBEGNZNMSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 description 5
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 5
- LCCVYZLUEHOBDC-UHFFFAOYSA-N methyl 2-(2,3-dimethylanilino)benzoate Chemical compound COC(=O)C1=CC=CC=C1NC1=CC=CC(C)=C1C LCCVYZLUEHOBDC-UHFFFAOYSA-N 0.000 description 5
- OKHORWCUMZIORR-UHFFFAOYSA-N methyl 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound C12=CC=C(OC)C=C2C(CC(=O)OC)=C(C)N1C(=O)C1=CC=C(Cl)C=C1 OKHORWCUMZIORR-UHFFFAOYSA-N 0.000 description 5
- 229940050176 methyl chloride Drugs 0.000 description 5
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 5
- 230000006824 pyrimidine synthesis Effects 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 4
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 4
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 4
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 125000003963 dichloro group Chemical group Cl* 0.000 description 4
- 229960002751 imiquimod Drugs 0.000 description 4
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- FUOQIQZCJJDBGD-UHFFFAOYSA-N methyl 2-(3-phenoxyphenyl)propanoate Chemical compound COC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 FUOQIQZCJJDBGD-UHFFFAOYSA-N 0.000 description 4
- RCUHEYOGXNRVCO-UHFFFAOYSA-N methyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylacetate Chemical compound CC(C)(C)OC(=O)NC(C(=O)OC)C1=CC=CC=C1 RCUHEYOGXNRVCO-UHFFFAOYSA-N 0.000 description 4
- VETACGBDFVVKGZ-UHFFFAOYSA-N methyl 2-[2-(2,6-dichloroanilino)phenyl]acetate Chemical compound COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl VETACGBDFVVKGZ-UHFFFAOYSA-N 0.000 description 4
- YNZYUHPFNYBBFF-UHFFFAOYSA-N methyl 2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound COC(=O)C(C)C1=CC=C(CC(C)C)C=C1 YNZYUHPFNYBBFF-UHFFFAOYSA-N 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- LWZMSGORCOQJAK-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-pyridin-2-ylthieno[3,2-e]thiazine-3-carboxamide Chemical compound OC=1C=2C=CSC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LWZMSGORCOQJAK-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 3
- RUHCATDGSSLXPZ-UHFFFAOYSA-N dicarboxyazaniumylideneazanide Chemical compound OC(=O)[N+](=[N-])C(O)=O RUHCATDGSSLXPZ-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- RERZNCLIYCABFS-UHFFFAOYSA-N harmaline Chemical compound C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 3
- ZFYFBPCRUQZGJE-JTQLQIEISA-N methyl (2s)-2-(6-methoxynaphthalen-2-yl)propanoate Chemical compound C1=C(OC)C=CC2=CC([C@H](C)C(=O)OC)=CC=C21 ZFYFBPCRUQZGJE-JTQLQIEISA-N 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229940049953 phenylacetate Drugs 0.000 description 3
- 229960002702 piroxicam Drugs 0.000 description 3
- 239000011241 protective layer Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 3
- 229960002871 tenoxicam Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GCOLCPKBBAZNQT-UHFFFAOYSA-N CCC1(CC(N(C=C2)C3=C2C(C2=CN(C(CC#N)(C4)CN4S(CC)(=O)=O)N=C2)=NC=N3)=O)OCCC2=C1NC1=C(CC)C=CC=C21 Chemical compound CCC1(CC(N(C=C2)C3=C2C(C2=CN(C(CC#N)(C4)CN4S(CC)(=O)=O)N=C2)=NC=N3)=O)OCCC2=C1NC1=C(CC)C=CC=C21 GCOLCPKBBAZNQT-UHFFFAOYSA-N 0.000 description 2
- 101001004391 Drosophila melanogaster Protein jim lovell Proteins 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 102000000887 Transcription factor STAT Human genes 0.000 description 2
- 108050007918 Transcription factor STAT Proteins 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960001929 meloxicam Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- CPJBKHZROFMSQM-UHFFFAOYSA-N methyl 2-(3-fluoro-4-phenylphenyl)propanoate Chemical compound FC1=CC(C(C)C(=O)OC)=CC=C1C1=CC=CC=C1 CPJBKHZROFMSQM-UHFFFAOYSA-N 0.000 description 2
- ZWJLFLBVYIJQAZ-UHFFFAOYSA-N methyl 2-(4-acetamidophenyl)acetate Chemical compound COC(=O)CC1=CC=C(NC(C)=O)C=C1 ZWJLFLBVYIJQAZ-UHFFFAOYSA-N 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000025915 regulation of apoptotic process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 229950000088 upadacitinib Drugs 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- QXVRLFIKHYCFJS-JTQLQIEISA-N (2s)-2-[4-(2-methylpropyl)phenyl]propanoyl chloride Chemical compound CC(C)CC1=CC=C([C@H](C)C(Cl)=O)C=C1 QXVRLFIKHYCFJS-JTQLQIEISA-N 0.000 description 1
- QHQSWYIJDFMBNE-OAQYLSRUSA-N (3r)-3-cyclopentyl-3-[4-[7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-4-yl]pyrazol-1-yl]propanenitrile Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C2=C3C=CN(C3=NC=N2)COCC[Si](C)(C)C)CCCC1 QHQSWYIJDFMBNE-OAQYLSRUSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- HDBXAQWZWHUVNC-UHFFFAOYSA-N 1-(2-methylpropyl)-4-propan-2-ylbenzene Chemical compound CC(C)CC1=CC=C(C(C)C)C=C1 HDBXAQWZWHUVNC-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- XTBAPWCYTNCZTO-UHFFFAOYSA-N 1H-isoindolone Natural products C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- TWDDAQGPSARLKW-NLLRYDLESA-N CC(C(N(C=C1)C2=C1C(C1=CN([C@H](CC#N)C3CCCC3)N=C1)=NC=N2)=O)C(C=C1)=CC(F)=C1C1=CC=CC=C1 Chemical compound CC(C(N(C=C1)C2=C1C(C1=CN([C@H](CC#N)C3CCCC3)N=C1)=NC=N2)=O)C(C=C1)=CC(F)=C1C1=CC=CC=C1 TWDDAQGPSARLKW-NLLRYDLESA-N 0.000 description 1
- WFIZMKWTKCVDDR-OLVCOQPYSA-N CC(C(N(C=C1)C2=C1C(C1=CN([C@H](CC#N)C3CCCC3)N=C1)=NC=N2)=O)C1=CC(C(C2=CC=CC=C2)=O)=CC=C1 Chemical compound CC(C(N(C=C1)C2=C1C(C1=CN([C@H](CC#N)C3CCCC3)N=C1)=NC=N2)=O)C1=CC(C(C2=CC=CC=C2)=O)=CC=C1 WFIZMKWTKCVDDR-OLVCOQPYSA-N 0.000 description 1
- ARUXBZJTNWYUHT-MCGOEHIVSA-N CC(C(N(C=C1)C2=C1C(N(C)[C@@H](C1)[C@H](C)CCN1C(CC#N)=O)=NC=N2)=O)C(C=C1)=CC(F)=C1C1=CC=CC=C1 Chemical compound CC(C(N(C=C1)C2=C1C(N(C)[C@@H](C1)[C@H](C)CCN1C(CC#N)=O)=NC=N2)=O)C(C=C1)=CC(F)=C1C1=CC=CC=C1 ARUXBZJTNWYUHT-MCGOEHIVSA-N 0.000 description 1
- HXBIKQXBTCEDAA-CNGZMADBSA-N CC(C)CC1=CC=C(C(C)C(N(C=C2)C3=C2C(N(C)[C@H]2CC[C@H](CS(NC)(=O)=O)CC2)=NC=N3)=O)C=C1 Chemical compound CC(C)CC1=CC=C(C(C)C(N(C=C2)C3=C2C(N(C)[C@H]2CC[C@H](CS(NC)(=O)=O)CC2)=NC=N3)=O)C=C1 HXBIKQXBTCEDAA-CNGZMADBSA-N 0.000 description 1
- RGLSQMRSAYBKKL-RZFKFIIISA-N CC1=C(CC(N(C=C2)C3=C2C(N(C)[C@H]2CC[C@H](CS(NC)(=O)=O)CC2)=NC=N3)=O)C2=CC(OC)=CC=C2N1C(C(C=C1)=CC=C1Cl)=O Chemical compound CC1=C(CC(N(C=C2)C3=C2C(N(C)[C@H]2CC[C@H](CS(NC)(=O)=O)CC2)=NC=N3)=O)C2=CC(OC)=CC=C2N1C(C(C=C1)=CC=C1Cl)=O RGLSQMRSAYBKKL-RZFKFIIISA-N 0.000 description 1
- ISOLENGYIMGDIF-AYWDJTEZSA-N CCC(C(N(C=C1)C2=C1C(N(C)[C@@H](C1)[C@H](C)CCN1C(CC#N)=O)=NC=N2)=O)C(C=C1)=CC=C1N(CC1=CC=CC=C11)C1=O Chemical compound CCC(C(N(C=C1)C2=C1C(N(C)[C@@H](C1)[C@H](C)CCN1C(CC#N)=O)=NC=N2)=O)C(C=C1)=CC=C1N(CC1=CC=CC=C11)C1=O ISOLENGYIMGDIF-AYWDJTEZSA-N 0.000 description 1
- HKWWLPMRTUARIU-UHFFFAOYSA-N CCS(N(C1)CC1(CC#N)N1N=CC(C2=NC=NC3=C2C=CN3C(C(C)C(C=C2)=CC(F)=C2C2=CC=CC=C2)=O)=C1)(=O)=O Chemical compound CCS(N(C1)CC1(CC#N)N1N=CC(C2=NC=NC3=C2C=CN3C(C(C)C(C=C2)=CC(F)=C2C2=CC=CC=C2)=O)=C1)(=O)=O HKWWLPMRTUARIU-UHFFFAOYSA-N 0.000 description 1
- NGSKAYZVTBIVQL-UHFFFAOYSA-N CCS(N(C1)CC1(CC#N)N1N=CC(C2=NC=NC3=C2C=CN3C(C(C)C2=CC(C(C3=CC=CC=C3)=O)=CC=C2)=O)=C1)(=O)=O Chemical compound CCS(N(C1)CC1(CC#N)N1N=CC(C2=NC=NC3=C2C=CN3C(C(C)C2=CC(C(C3=CC=CC=C3)=O)=CC=C2)=O)=C1)(=O)=O NGSKAYZVTBIVQL-UHFFFAOYSA-N 0.000 description 1
- WHGBZULWQIZBGH-UHFFFAOYSA-N CCS(N(C1)CC1(CC#N)N1N=CC(C2=NC=NC3=C2C=CN3C(C(C)C2=CC(OC3=CC=CC=C3)=CC=C2)=O)=C1)(=O)=O Chemical compound CCS(N(C1)CC1(CC#N)N1N=CC(C2=NC=NC3=C2C=CN3C(C(C)C2=CC(OC3=CC=CC=C3)=CC=C2)=O)=C1)(=O)=O WHGBZULWQIZBGH-UHFFFAOYSA-N 0.000 description 1
- QVTCZXNVECTFQY-UHFFFAOYSA-N CCS(N(C1)CC1(CC#N)N1N=CC(C2=NC=NC3=C2C=CN3C(C(C)C2=CC=C(CC(C)C)C=C2)=O)=C1)(=O)=O Chemical compound CCS(N(C1)CC1(CC#N)N1N=CC(C2=NC=NC3=C2C=CN3C(C(C)C2=CC=C(CC(C)C)C=C2)=O)=C1)(=O)=O QVTCZXNVECTFQY-UHFFFAOYSA-N 0.000 description 1
- MNVBBGUKSUQNEC-UHFFFAOYSA-N CCS(N(C1)CC1(CC#N)N1N=CC(C2=NC=NC3=C2C=CN3C(CC(C2=C3)=C(C)N(C(C(C=C4)=CC=C4Cl)=O)C2=CC=C3OC)=O)=C1)(=O)=O Chemical compound CCS(N(C1)CC1(CC#N)N1N=CC(C2=NC=NC3=C2C=CN3C(CC(C2=C3)=C(C)N(C(C(C=C4)=CC=C4Cl)=O)C2=CC=C3OC)=O)=C1)(=O)=O MNVBBGUKSUQNEC-UHFFFAOYSA-N 0.000 description 1
- QVTCZXNVECTFQY-NRFANRHFSA-N CCS(N(C1)CC1(CC#N)N1N=CC(C2=NC=NC3=C2C=CN3C([C@@H](C)C2=CC=C(CC(C)C)C=C2)=O)=C1)(=O)=O Chemical compound CCS(N(C1)CC1(CC#N)N1N=CC(C2=NC=NC3=C2C=CN3C([C@@H](C)C2=CC=C(CC(C)C)C=C2)=O)=C1)(=O)=O QVTCZXNVECTFQY-NRFANRHFSA-N 0.000 description 1
- SRQFGVFSJNWAPP-GGAORHGYSA-N CC[C@H](CN(C1)C(NCC(F)(F)F)=O)[C@H]1C1=CN=C2N1C(C=CN1C(C(C=CC=C3)=C3NC3=C(C)C(C)=CC=C3)=O)=C1N=C2 Chemical compound CC[C@H](CN(C1)C(NCC(F)(F)F)=O)[C@H]1C1=CN=C2N1C(C=CN1C(C(C=CC=C3)=C3NC3=C(C)C(C)=CC=C3)=O)=C1N=C2 SRQFGVFSJNWAPP-GGAORHGYSA-N 0.000 description 1
- YGTLHHKWQFAYIG-ZBLYBZFDSA-N CC[C@H](CN(C1)C(NCC(F)(F)F)=O)[C@H]1C1=CN=C2N1C(C=CN1C(CC(C3=C4)=C(C)N(C(C(C=C5)=CC=C5Cl)=O)C3=CC=C4OC)=O)=C1N=C2 Chemical compound CC[C@H](CN(C1)C(NCC(F)(F)F)=O)[C@H]1C1=CN=C2N1C(C=CN1C(CC(C3=C4)=C(C)N(C(C(C=C5)=CC=C5Cl)=O)C3=CC=C4OC)=O)=C1N=C2 YGTLHHKWQFAYIG-ZBLYBZFDSA-N 0.000 description 1
- SPRAANHTYRGZKY-QUCCMNQESA-N CC[C@H](CN(C1)C(NCC(F)(F)F)=O)[C@H]1C1=CN=C2N1C(C=CN1C(CC(C=C3)=CC=C3NC(C)=O)=O)=C1N=C2 Chemical compound CC[C@H](CN(C1)C(NCC(F)(F)F)=O)[C@H]1C1=CN=C2N1C(C=CN1C(CC(C=C3)=CC=C3NC(C)=O)=O)=C1N=C2 SPRAANHTYRGZKY-QUCCMNQESA-N 0.000 description 1
- XIOFLJSSCMPIOG-QUCCMNQESA-N CC[C@H](CN(C1)C(NCC(F)(F)F)=O)[C@H]1C1=CN=C2N1C(C=CN1C(CC(C=CC=C3)=C3NC(C(Cl)=CC=C3)=C3Cl)=O)=C1N=C2 Chemical compound CC[C@H](CN(C1)C(NCC(F)(F)F)=O)[C@H]1C1=CN=C2N1C(C=CN1C(CC(C=CC=C3)=C3NC(C(Cl)=CC=C3)=C3Cl)=O)=C1N=C2 XIOFLJSSCMPIOG-QUCCMNQESA-N 0.000 description 1
- YOVIVUCFIWKQRT-GOHWNWGWSA-N C[C@H](C(N(C=C1)C2=C1C(N(C)[C@@H](C1)[C@H](C)CCN1C(CC#N)=O)=NC=N2)=O)C(C=CC1=C2)=CC1=CC=C2OC Chemical compound C[C@H](C(N(C=C1)C2=C1C(N(C)[C@@H](C1)[C@H](C)CCN1C(CC#N)=O)=NC=N2)=O)C(C=CC1=C2)=CC1=CC=C2OC YOVIVUCFIWKQRT-GOHWNWGWSA-N 0.000 description 1
- JIOKGBWXHAZQOI-ZBLYBZFDSA-N C[C@H](CCN(C1)C(CC#N)=O)[C@H]1N(C)C1=NC=NC2=C1C=CN2C(C(C=CC=C1)=C1NC1=C(C)C(C)=CC=C1)=O Chemical compound C[C@H](CCN(C1)C(CC#N)=O)[C@H]1N(C)C1=NC=NC2=C1C=CN2C(C(C=CC=C1)=C1NC1=C(C)C(C)=CC=C1)=O JIOKGBWXHAZQOI-ZBLYBZFDSA-N 0.000 description 1
- JSLXILRTVBHNSR-BCHFMIIMSA-N C[C@H](CCN(C1)C(CC#N)=O)[C@H]1N(C)C1=NC=NC2=C1C=CN2C(C(C=CC=C1)=C1NC1=C(C)C(Cl)=CC=C1)=O Chemical compound C[C@H](CCN(C1)C(CC#N)=O)[C@H]1N(C)C1=NC=NC2=C1C=CN2C(C(C=CC=C1)=C1NC1=C(C)C(Cl)=CC=C1)=O JSLXILRTVBHNSR-BCHFMIIMSA-N 0.000 description 1
- IPXNOHUDBHSFRF-DFXYEROKSA-N C[C@H](CCN(C1)C(CC#N)=O)[C@H]1N(C)C1=NC=NC2=C1C=CN2C(CC(C1=C2)=C(C)N(C(C(C=C3)=CC=C3Cl)=O)C1=CC=C2OC)=O Chemical compound C[C@H](CCN(C1)C(CC#N)=O)[C@H]1N(C)C1=NC=NC2=C1C=CN2C(CC(C1=C2)=C(C)N(C(C(C=C3)=CC=C3Cl)=O)C1=CC=C2OC)=O IPXNOHUDBHSFRF-DFXYEROKSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229940125772 JTE-052 Drugs 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical compound CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
- 101150058731 STAT5A gene Proteins 0.000 description 1
- 101150063267 STAT5B gene Proteins 0.000 description 1
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 1
- 102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 description 1
- 102100023980 Signal transducer and activator of transcription 6 Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- QZXCCPZJCKEPSA-UHFFFAOYSA-N chlorfenac Chemical compound OC(=O)CC1=C(Cl)C=CC(Cl)=C1Cl QZXCCPZJCKEPSA-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-M fenoprofen(1-) Chemical compound [O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-M 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000004246 indolin-2-yl group Chemical group [H]N1C(*)=C([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- YNZYUHPFNYBBFF-NSHDSACASA-N methyl (2s)-2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound COC(=O)[C@@H](C)C1=CC=C(CC(C)C)C=C1 YNZYUHPFNYBBFF-NSHDSACASA-N 0.000 description 1
- CNIPMLJEWLMTCO-UHFFFAOYSA-N methyl 2-(3-chloro-2-methylanilino)benzoate Chemical compound COC(=O)C1=CC=CC=C1NC1=CC=CC(Cl)=C1C CNIPMLJEWLMTCO-UHFFFAOYSA-N 0.000 description 1
- ULWVQWBFONIXFV-UHFFFAOYSA-N methyl 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoate Chemical compound C1=CC(C(C)C(=O)OC)=CC=C1CC1C(=O)CCC1 ULWVQWBFONIXFV-UHFFFAOYSA-N 0.000 description 1
- ONWPLBKWMAUFGZ-UHFFFAOYSA-N methyl 2-acetyloxybenzoate Chemical compound COC(=O)C1=CC=CC=C1OC(C)=O ONWPLBKWMAUFGZ-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- JKRHDMPWBFBQDZ-UHFFFAOYSA-N n'-hexylmethanediimine Chemical compound CCCCCCN=C=N JKRHDMPWBFBQDZ-UHFFFAOYSA-N 0.000 description 1
- HJWLJNBZVZDLAQ-UHFFFAOYSA-N n-methyl-1-[4-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]methanesulfonamide Chemical compound C1CC(CS(=O)(=O)NC)CCC1N(C)C1=NC=NC2=C1C=CN2 HJWLJNBZVZDLAQ-UHFFFAOYSA-N 0.000 description 1
- UHNHTTIUNATJKL-UHFFFAOYSA-N n-methylmethanesulfonamide Chemical compound CNS(C)(=O)=O UHNHTTIUNATJKL-UHFFFAOYSA-N 0.000 description 1
- LTRANDSQVZFZDG-SNVBAGLBSA-N naproxol Chemical compound C1=C([C@H](C)CO)C=CC2=CC(OC)=CC=C21 LTRANDSQVZFZDG-SNVBAGLBSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 150000003233 pyrroles Chemical group 0.000 description 1
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention relates to an external anti-inflammatory drug, in particular to a coupled compound drug and its application.
- the JAK-STAT signaling pathway is a signal transduction pathway stimulated by cytokines discovered in recent years and participates in many important biological processes such as cell proliferation, differentiation, apoptosis, and immune regulation. Many cytokines and growth factors transmit signals through the JAK-STAT signaling pathway, including IL (interleukin), GM-CSF (granulocyte/macrophage colony-stimulating factor), GH (growth hormone), EGF (epidermal growth factor), PDGF (platelet-derived factor) and IFN (interferon), etc.
- IL interleukin
- GM-CSF granulocyte/macrophage colony-stimulating factor
- GH growth hormone
- EGF epidermal growth factor
- PDGF platelet-derived factor
- IFN interferon
- the JAK-STAT signaling pathway consists of three components, namely tyrosine kinase-related receptors, tyrosine kinases (JAKs) and transcription factors (STATs).
- tyrosine kinase-related receptors binds to the ligand
- JAKs tyrosine kinases
- STATs transcription factors
- the JAK family includes JAK1, JAK2, JAK3, and TYK2. These kinases control seven different STATs, which are STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. It is by controlling these STATs that cytokines and growth factors can control cell proliferation, differentiation, apoptosis, and immune regulation. Many diseases are caused by JAK and STAT mutations. By modulating and selectively inhibiting certain JAKs, these diseases can be effectively treated.
- JAK-STAT is a relatively simple signaling pathway, it is still involved in many cellular functions.
- JAK inhibitors There are dozens of JAK inhibitors currently on the market and under development. Most JAK inhibitor projects aim to maximize efficacy and minimize side effects by selectively inhibiting a certain JAK-STAT transmission.
- systemic drug administration systemic drug administration
- the local administration of JAK inhibitors can enhance the efficacy while reducing systemic side effects.
- Many JAK inhibitor projects under development also take organ selectivity as the ultimate goal to maximize efficacy/risk.
- the purpose of the present invention is also to maximize the efficacy of skin administration and minimize systemic toxicity through external (skin) administration, combined with optimization of the compound structure.
- skin diseases including psoriasis, vitiligo, alopecia areata, etc.
- JAK inhibitors on the market and under development on various JAK-STATs have also been very clear.
- By modifying the chemical structure of existing known JAK inhibitors so that they can penetrate more of the protective layer of the skin skin-selective drug delivery can also be achieved.
- a product whose structure is optimized for a known compound has a relatively shorter development cycle, lower risk of efficacy failure, lower possibility of unknown toxicity, and lower R&D costs. Be low.
- Compound structure optimization to increase compound permeability can change the physical and chemical properties of the compound by adding non-functional groups to the known compound structure so that it can penetrate more of the protective layer of the skin. This practice is also called prodrug technology. It is widely used in drug research and development.
- the present invention is aimed at the technical problems of high dosage and side effects of existing known JAK inhibitors.
- the structure of the known JAK compounds is optimized so that it can effectively achieve selective delivery to the skin, thereby increasing the treatment of skin diseases. effectiveness and reduced systemic dose and side effects.
- by coupling known JAK inhibitors with other small molecule compounds structural optimization and skin-selective drug delivery can be achieved.
- the present invention provides the following technical solutions.
- the chemical bond between the linker and the JAK inhibitor is unstable in human skin, thus hydrolyzing and releasing the active ingredient, the JAK inhibitor.
- the bond between the linker and the coupling small molecule is also unstable, thereby releasing the coupling small molecule.
- the linker itself has a known simple chemical structure and is non-toxic.
- the present invention provides the following technical solutions.
- the present invention provides an anti-inflammatory compound, or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate, the structure of which is as follows: (I) shown:
- A is the dehydrogenated group of an amine compound with JAK inhibitory activity
- Y is a direct connection; or -(CH 2 )-O- or -(CH 2 )-;
- B is a group formed by dehydroxylation of carboxylic acid compound B 1 containing a carboxyl group or a group formed by dehydrogenation of hydroxyl-containing compound B 2 ; wherein, when the carboxylic acid compound B 1 is dehydroxylated to form a group (i.e. when B is B 1 ), the Y group is directly connected or -(CH 2 )-O-; when the hydroxyl-containing compound B 2 is dehydrogenated to form a group (i.e. B is B 2 ), the Y group is -(CH 2 )-.
- the anti-inflammatory compound described above in the present invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate,
- the structure is shown as general formula (II) or general formula (IIa):
- R 1 is selected from unsubstituted or R a substituted pyrazolyl or pyrrolyl; or -N(CH 3 )-Cy;
- R 1a represents C1-C6 alkylaminoacyl substituted by halogen and/or C1 -C6 alkyl substituted pyrrole ring;
- Cy is a five-membered or six-membered carbocyclic ring, a five-membered or six-membered nitrogen-containing heterocyclic ring that is unsubstituted or substituted by R b , and the R a and R b are each independently containing an acyl group, a disulfonyl group, a cyano group, an amino group Or C1-C6 alkyl substituted amino, four-membered, five-membered or six-membered nitrogen-containing heterocyclic group or at least one or two groups of the nitrogen-containing heterocyclic group substituted by C1-C6 alkyl; preferably Said R a and R b each independently comprise one of acyl or disulfonyl groups and are selected from cyano group, amino group or C1-C6 alkyl substituted amino group, four-membered, five-membered or six-membered nitrogen-containing heterocyclic group or A group composed of at least one group of the nitrogen-
- R 2 in general formula (II) and general formula (IIa) is both -B, which is the group -B 1 formed by removing the hydroxyl group of carboxylic acid compound B 1 , selected from R 4 -Ar-R 3 -CO -,
- R 3 is selected from C1-C6 alkylene; -NH-, R 5 NH- or C1-C6 alkylene substituted by C1-C6 alkoxyamide group; or directly connected, that is, the Ar group is directly connected to - CO-;
- R 3 is preferably methyl-substituted or unsubstituted methylene, -C 2 H 4 -, or directly connected;
- R 5 is C1-C6 alkylene; wherein, the C1-C6 alkylene can be Substituted by halogen (preferably the halogen is selected from one or more of fluorine, chlorine or bromine);
- Ar is an aromatic ring group, preferably selected from benzene ring; naphthalene ring or aromatic heterocyclic ring; selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 acyl or C1-C6 alkoxy
- a benzene ring, a naphthalene ring or an aromatic heterocyclic ring or an aromatic fused heterocyclic ring substituted by more than one group here, the aromatic heterocyclic ring is preferably a benzo nitrogen-containing or oxygen heterocyclic ring such as a benzopyrrole ring);
- Ar is more preferably nitrogen-containing aromatic heterocycles of atoms;
- R 4 is halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl containing C1-C6 cycloalkanoyl, C1-C6 alkanoamide or aromatic fused heterocyclic amide, C1-C6 carbon Acyloxy, halogen-substituted benzoyl, C1-C6 alkyl or halogen-substituted or unsubstituted phenoxy, C1-C6 alkyl or halogen-substituted or unsubstituted phenyl or aromatic fused heterocycle, C1-C6 Alkyl or halogen-substituted or unsubstituted phenylamino group, or R 4 may not be present; wherein, the C1-C6 alkoxy group may also form a bridged ring with Ar.
- the anti-inflammatory compound described above in the present invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate, wherein Cy is a substituted cyclohexyl group or a substituted piperidinyl group; preferably the substituted cyclohexyl group is a cyclohexyl group substituted by an amino group and a disulfonyl group, and the substituted piperidinyl group is a substituted cyclohexyl group containing an acyl group or a disulfonyl group and -CN substituted piperidinyl.
- the compound of the present invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate, wherein it is an amine compound A coupling compound obtained by the condensation reaction of A and carboxylic acid compound B 1 .
- the compound described above in the present invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate, wherein A is selected from The dehydrogenated group of any amine compound from the following compound group: tofacitinib, baricitinib, oclacitinib, ruxolitinib, upapatinib, and diglotinib:
- A is the group formed after dehydrogenation of tofacitinib, ruxolitinib and baricitinib.
- the anti-inflammatory compound of the present invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate, wherein -B is selected from 1 A group with the hydroxyl group removed from any of the following groups of carboxylic acid species: ibuprofen, (S)-(+)-ibuprofen, naproxen, fenoprofen, flurbiprofen, roprofen Soprofenac, Ketoprofen, Diclofenac, Etodolac, Actarid, Indomethacin, N-Boc-L-phenylglycine, Aspirin, Indobufen, Mefenamic acid and Tolfenamide acid:
- the anti-inflammatory compound of the present invention is selected from the group consisting of An amine compound A among tofacitinib, baricitinib, upatinib, oclacitinib and ruxolitinib is combined with ibuprofen, (S)-(+)-ibbuprofen Condensation reaction of a carboxylic acid compound B 1 among fen, naproxen, fenoprofen, flurbiprofen, loxoprofen acid, ketoprofen, etodolac, actuali and indomethacin
- the obtained coupling compound preferably, the amine compound is tofacitinib, ruxolitinib and baricitinib.
- the anti-inflammatory compound of the present invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate, is as follows: Any of the compounds:
- the anti-inflammatory compound of the present invention is Any of the following specific compounds:
- the anti-inflammatory compound of the present invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate, It is one of the following specific compounds:
- the anti-inflammatory compound of the invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate , its structure is shown in general formula (III):
- R 1 has the same meaning as R 1 in general formula (II);
- R 1a has the same meaning as R 1a in general formula (IIa);
- R 2 ' in general formula (III) and general formula (IIIa) are both YB, and B is B 1 in general formula (II) or (IIa), or B is B 2 ; wherein, the group B 1 is a group formed by dehydroxylation of carboxylic acid compound B 1 , in which case Y- is (CH 2 )-O-; said group B 2 is a group formed by dehydrogenation of hydroxyl-containing compound B 2 , in which case Y - is -(CH 2 )-; the group B 1 has the same meaning as the R 2 group in the general formula (II) or the general formula (IIa); the group B 2 is R c -CO-NH- R d , where R c is a 4-hydroxy-benzothiazinedioxide-3-group represented by the following structural formula (a) (where the benzene ring can be substituted by halogen or C1-C6 alkyl) or is the following structural formula The 4-hydroxy-Re substituted
- R d is thiazole, isothiazole, oxazole, isoxazole, or pyridine or their groups substituted by C1-C6 alkyl or halogen, preferably thiazole, isoxazole substituted by methyl; and not Substituted pyridyl; R e is C1-C6 alkyl or halogen (preferably the halogen is selected from one or more of fluorine, chlorine or bromine), the arrow next to R e in formula (b) indicates that it is on the thiophene ring
- the substitution position of can be any hydrogen atom connected to a carbon that can be substituted.
- the anti-inflammatory compound of the present invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate, wherein, -B 1 is the group after removing the hydroxyl group of any one of the following carboxylic acid substances: ibuprofen, (S)-(+)-ibuprofen, naproxen, fenoprofen, Flurbiprofen, loxoprofen acid, ketoprofen, diclofenac, etodolac, actualide, indomethacin, N-Boc-L-phenylglycine, aspirin, indobufen, mefenfen Tolfenamic acid and tolfenamic acid:
- -B 2 is the group obtained by removing hydrogen from a hydroxyl-containing compound among the following specific compounds:
- the anti-inflammatory compound of the present invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate, is obtained by The preparation method including the following steps is obtained:
- the A-CH 2 -OH compound is preferably prepared by the following step 1): forming the amine compound A into the A-CH 2 -OH compound.
- the anti-inflammatory compound described above in the present invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate, wherein A A group that removes hydrogen from any amine compound selected from the following group of compounds: tofacitinib, baricitinib, oclacitinib, ruxolitinib, upapatinib and digoti Ni:
- A is the group formed after dehydrogenation of tofacitinib, ruxolitinib and baricitinib. In certain embodiments, it is preferred that A is a group formed by any one of baricitinib, oclacitinib or upadacitinib.
- the anti-inflammatory compound described above in the present invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate, It is any one of the following specific compounds:
- the present invention also provides methods for preparing the aforementioned anti-inflammatory compounds, or their stereoisomers, tautomers, nitrogen oxides, metabolites, prodrugs, pharmaceutically acceptable salts or solvates. , including the following steps:
- a and B are obtained by a condensation reaction in which water is lost in the presence of a catalyst and an organic solvent.
- the catalyst is EDCI (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride), DCC (bicyclic Hexylcarbodiimide), CDI (N, N-carbonyldiimidazole), DMTMM (4-(4,6-dimethoxytriazine)-4-methylmorpholine hydrochloride), HATU (2 -(7-Azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate), HCTU (6-chlorobenzotriazole-1,1,3, One or more of 3-tetramethylurea hexafluorophosphate), PyBOP (benzotriazol-1-yl-oxytripyrrolidinylphosphonate hexafluorophosphate), NPC; preferably the organic solvent One or more selected from DCM (dichloromethane), DMF
- the preparation method of the anti-inflammatory compound of the present invention includes the following steps: using A-CH 2 OH and B to undergo a water loss condensation reaction to obtain it.
- the preparation method of the anti-inflammatory compound of the present invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate, it Obtained by a preparation method including the following steps:
- the A-CH 2 -OH compound is preferably prepared through the following step 1): forming the amine compound A into the A-CH 2 -OH compound.
- step 1) includes: a) adding (2-(chloromethoxy)ethyl)trimethylsilane to A in the presence of a catalyst and a solvent to generate A -CH 2 OC 2 H 4 -Si(CH 3 ) 3 ; and b) A-CH 2 OC 2 H 4 -Si(CH 3 ) 3 in the presence of a catalyst and a solvent to form A-CH 2 OH; step 2) is : A-CH 2 OH reacts directly with the acid chloride formed by the B 1 compound or the B 2 compound to form A-CH 2 OB;
- step b) the reaction is carried out in the presence of TFA (trifluoroacetic acid) as a catalyst and DCM (dichloromethane) as a solvent; or in step 2), in the presence of Et 3 N (triethylamine) as a catalyst and A-CH 2 OH reacts with the acid chloride formed by the B 1 compound in the presence of DCM (dichloromethane) as the solvent or in the presence of PPh3 (triphenylphosphine) and DIAD (diisopropyl azodicarboxylate) as the catalyst and THF A-CH 2 OH reacts with the B 2 compound in the presence of (tetrahydrofuran) as a solvent.
- TFA trifluoroacetic acid
- DCM dichloromethane
- step 2 the reaction is carried out in the presence of Et 3 N (triethylamine) as a catalyst and A-CH 2 OH reacts with the acid chloride formed by the B 1 compound in the presence of DCM
- the present invention provides a pharmaceutical use, that is, providing the anti-inflammatory compound, or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or Solvates are used for the preparation of anti-inflammatory pharmaceutical preparations or pharmaceutical compositions (preferably external pharmaceutical compositions).
- the present invention also provides an anti-inflammatory pharmaceutical preparation or pharmaceutical composition (preferably an external pharmaceutical composition), which contains the anti-inflammatory compound described in any of the previous items of the present invention, or its stereoisomer or tautomer. compounds, nitrogen oxides, metabolites, prodrugs, pharmaceutically acceptable salts or solvates.
- the present invention finds that the compound of the present invention has a dissolution rate of 0.04%-50% per day, thereby increasing the transdermal ability of known JAK inhibitors.
- Figure 1 is a PASI score curve chart of the mouse psoriasis model test by applying the ointment made of CPD-029 of the present invention through the skin;
- Figure 2 is a PASI score curve chart of the mouse psoriasis model test by applying the ointment made of CPD-028 of the present invention through the skin;
- Figure 3 is a PASI score curve chart of the mouse psoriasis model test by applying the ointment made of CPD-027 of the present invention through the skin;
- Figure 4 is a PASI score curve diagram of the mouse psoriasis model test by applying the ointment made of CPD-017 of the present invention through the skin;
- Figure 5 is a PASI score curve of the mouse psoriasis model test by applying the ointment made of CPD-002 of the present invention through the skin.
- the inventor unexpectedly discovered through intensive research that coupling anti-inflammatory drug compounds containing carboxylic acid or hydroxyl groups with JAK inhibitor compounds to form coupling compounds with acyloxy groups and or methoxy groups has high curative effect and can control the release of drug activity. Effect.
- the anti-inflammatory compound provided by the present invention or its stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, pharmaceutically acceptable salt or solvate, has a structure such as general formula (I) Shown:
- A is the dehydrogenated group of an amine compound with JAK inhibitory activity
- Y is directly connected or -(CH 2 )-O-;
- B is a group formed by dehydroxylation of carboxylic acid compound B 1 with anti-inflammatory effect or a group formed by dehydrogenation of hydroxyl-containing compound B 2 .
- the compounds of general formula (I) provided by the present invention actually include two categories.
- the first category of compounds refers to the case where A is directly connected, and its structural formula is as shown in (II) or (IIa).
- R 1 is selected from unsubstituted or Ra-substituted pyrazolyl or -N(CH 3 )-Cy;
- R 1a represents C1-C6 alkylaminoacyl substituted by halogen and/or C1-C6 alkyl substitution The pyrrole ring;
- Cy is a five-membered or six-membered carbocyclic ring, a five-membered or six-membered nitrogen-containing heterocyclic ring that is unsubstituted or substituted by R b , and the R a and R b are each independently containing an acyl group, a disulfonyl group, a cyano group, an amino group Or C1-C6 alkyl substitutes at least one or two groups in the amino group; preferably, R a and R b are each independently one of acyl or disulfonyl and selected from cyano group, amino or C1-C6 Alkyl substitutes at least one group in the amino group, wherein the C1-C6 alkyl group can be substituted by halogen;
- R 2 in general formula (II) and general formula (IIa) is both -B, which is the group -B 1 formed by removing the hydroxyl group of carboxylic acid compound B 1 , selected from R 4 -Ar-R 3 -CO -,
- R 3 is selected from C 1 -C 4 alkylene; -NH-, R 5 NH- or C1-C6 alkylene substituted by C1-C6 alkoxyamide group; or directly connected, that is, the Ar group directly Connected to -CO-;
- R 3 is preferably methyl-substituted or unsubstituted methylene, -C 2 H 4 -, or directly connected;
- R 5 is C1-C6 alkylene; wherein, the C1-C6 alkylene The group can be substituted by halogen (preferably the halogen is selected from one or more types of fluorine, chlorine or bromine);
- Ar is an aromatic ring group, preferably selected from benzene ring; naphthalene ring or aromatic heterocyclic ring; selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 acyl or C1-C6 alkoxy benzene ring, naphthalene ring or aromatic heterocyclic ring or aromatic condensed heterocyclic ring substituted by a group (here, the aromatic heterocyclic ring is preferably a benzo nitrogen-containing or oxygen heterocyclic ring such as a benzopyrrole ring); Ar is more preferably an aromatic nitrogen-containing atom. Heterocycle;
- R 6 is halogen, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 alkyl containing cycloalkanoyl;
- R 6 is: C1-C6 alkyl or aromatic ring or aromatic fused ring or aromatic fused heterocycle containing acyl group and/or amine group, such as C1-C6 alkanoic acid amide group or aromatic fused heterocyclic amide group, C1-C6 carbon Acyloxy, halogen-substituted benzoyl, C1-C6 alkyl or halogen-substituted or unsubstituted phenoxy, C1-C6 alkyl or halogen-substituted or unsubstituted phenyl or aromatic fused heterocycle, C1-C6 Alkyl or halogen-substituted or unsubstituted phenylamino group, or R 6 may be absent; wherein, the C1-C6 alkoxy group may also form a bridged ring with Ar.
- acyl group and/or amine group such as C1-C6 alkanoic acid amide group or aromatic fused hetero
- C1-C6 mean that the number of carbon atoms is 1-6; for example, “C1-C6 alkyl” refers to an alkyl group having 1-6 carbon atoms.
- C1-C6 alkoxy and “C1-C6 acyl” appearing in this specification respectively refer to an alkoxy group with 1-6 carbon atoms and an alkoxy group with 1-6 carbon atoms.
- C1-C6 alkylamido group refers to an alkyl group containing an amide group and having 1-6 carbon atoms
- C1-C6 carbonyloxy group refers to an acyl group containing Oxygen-CO-O alkyl group or cycloalkyl group with 1-6 carbon atoms
- C1-C6 alkyl group containing C1-C6 cycloalkanoyl group refers to an alkyl group with 1-6 carbon atoms that contains hydrogen on the carbon atom.
- C1-C6 cycloalkanoyl substitution that is, "C1-C6 alkyl group containing C1-C6 cycloalkanoyl group” is equivalent to "C1-C6 alkyl group substituted by C1-C6 cycloalkanoyl group”.
- C1-C6 mentioned in the present invention can specifically be “C1-C6", “C1-C5", “C1-C4", “C1-C3” or “C1-C2", or it can be C1, that is, only one the case of carbon atoms.
- the first major type of compound mentioned above is compound AB (specifically AB 1 ) formed by dehydrogenation of amine compound A with JAK inhibitory activity and dehydroxylation of carboxylic acid compound B 1 .
- the compound of general formula (I) provided by the present invention includes the second major type of compound, and its structural formula is as shown in general formula (III):
- R 1 has the same meaning as R 1 in general formula (II);
- R 1a has the same meaning as R 1a in general formula (IIa);
- R 2 ' in general formula (III) and general formula (IIIa) are both -YB, said Y is -(CH 2 )-O-, and B is -B 1 in general formula (II) or (IIa) , that is, the group -B 1 formed by removing the hydroxyl group of carboxylic acid compound B 1 ; or B is -B 2 , and -B 2 is R c -CO-NH-R d , where R c is the following structural formula ( 4-Hydroxy-benzothiazine dioxide-3-group shown in a) (where the benzene ring may be substituted by halogen or C 1 -C 4 alkyl) or 4- as shown in the following structural formula (b) Hydroxy-Re substituted thienothiazine dioxide-3-group, in which -CO-NH-R d is attached to the 3-position of the thiazine ring,
- R d is thiazole, isothiazole, oxazole, isoxazole, or pyridine or their groups substituted by C1-C6 alkyl or halogen, preferably thiazole, isoxazole substituted by methyl; and not Substituted pyridyl; R e is C1-C6 alkyl or halogen (preferably the halogen is selected from one or more of fluorine, chlorine or bromine), the arrow next to R e in formula (b) indicates that it is on the thiophene ring
- the substitution position of can be any hydrogen atom connected to a carbon that can be substituted.
- the second major type of compounds described in the present invention is obtained by the condensation reaction of A-CH 2 OH and B with the loss of water.
- A-CH 2 -OH compound is obtained by direct reaction with the acid chloride of B or the B compound; wherein the A-CH 2 -OH compound is obtained through step 1): A is formed into an A-CH 2 -OH compound.
- the scope of the compound of general formula (I) of the present invention actually includes various stereoisomers, tautomers, and nitrogen oxides that can be obtained from the compound by those skilled in the art based on common knowledge.
- metabolites, prodrugs, pharmaceutically acceptable salts or solvates that is to say these compounds, and their various stereoisomers, tautomers, nitrogen oxides, metabolites, prodrugs, pharmaceutical Acceptable salts or solvates, etc.
- those skilled in the art can make various modifications and improvements to the compounds based on common knowledge, and the resulting substances can be used in the present invention to achieve the strong transdermal properties and controlled release of drugs possessed by the compounds of the present invention.
- high curative effect and other special effects therefore all belong to the protection scope of the present invention.
- Table 1 below shows the structural formula and compound name of the target compounds prepared in each example.
- Step 1 3-((3R,4R)-4-methyl-3-(methyl(7-(2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[ Synthesis of 2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropionitrile
- Step 2 3-((3R,4R)-3-((7-(hydroxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4 -Synthesis of methylpiperidin-1-yl)-3-oxopropionitrile
- trifluoroacetic acid (6.44g, 56.5mmol) was slowly added dropwise to 3-((3R, 4R)-4-methyl-3-(methyl(7-(2- (Trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropionitrile ( 5g, 11.3mmol) in dichloromethane (100mL), remove the ice water bath after half an hour, raise the temperature to room temperature and continue stirring for 24 hours. At 0°C, add saturated sodium bicarbonate solution to the above reaction solution to adjust the pH to 8. The mixture was then poured into a separatory funnel and separated.
- Step 3 (4-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)(methyl)amino)-7H-pyrrolo[2, Synthesis of 3-d]pyrimidin-7-yl)methyl(S)-2-(4-isobutylphenyl)propionate
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- N-Methyl-1-((1R,4R)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (olatidine Ni, 338 mg, 1 mmol), 4-dimethylaminopyridine (DMAP, 122 mg, 1 mmol), (S)-(+)-2-(4-isobutylphenyl)propionic acid ((S)-(+)- Ibuprofen, 247 mg, 1.2 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 288 mg, 1.5 mmol) were dissolved in dichloromethane (10 mL) , stirred at room temperature for 16 hours.
- dichloromethane 10 mL
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- N-methyl-1-((trans)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (olacitinib , 203 mg, 0.6 mmol), 4-dimethylaminopyridine (DMAP, 73 mg, 0.6 mmol), 2-(2-fluoro-4-biphenyl)propionic acid (flurbiprofen, 191 mg, 0.78 mmol) and 1- (3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 173 mg, 0.9 mmol) was dissolved in dichloromethane (10 mL) and stirred at room temperature for 16 hours.
- dichloromethane 10 mL
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- N-methyl-1-((trans)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (olacitinib , 203 mg, 0.6 mmol), 4-dimethylaminopyridine (DMAP, 73 mg, 0.6 mmol), 1,8-diethyl-1,3,4,9-tetrahydropyran[3,4-b]indole Indole-1-acetic acid (etodolac, 224 mg, 0.78 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 173 mg, 0.9 mmol) were dissolved in di into methyl chloride (15 mL) and stirred at room temperature for 3 hours.
- DMAP 1,8-diethyl-1,3,4,9-tetrahydropyran[3,4-b]indole
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- N-methyl-1-((trans)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (olacitinib , 203 mg, 0.6 mmol), 4-dimethylaminopyridine (DMAP, 73 mg, 0.6 mmol), 2-(3-benzoylphenyl)propionic acid (ketoprofen, 198 mg, 0.78 mmol) and 1-(3 -Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 173 mg, 0.9 mmol) was dissolved in dichloromethane (15 mL) and stirred at room temperature for 18 hours.
- dichloromethane 15 mL
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- N-methyl-1-((trans)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (olacitinib , 203 mg, 0.6 mmol), 4-dimethylaminopyridine (DMAP, 73 mg, 0.6 mmol), (S)-(+)-2-(6-methoxy-2-naphthyl)propionic acid (naproxen , 180 mg, 0.78 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 173 mg, 0.9 mmol) were dissolved in dichloromethane (15 mL) at room temperature.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- N-methyl-1-((trans)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (olacitinib , 203 mg, 0.6 mmol), 4-dimethylaminopyridine (DMAP, 73 mg, 0.6 mmol), 2-((3-chloro-2-methylphenyl)amino)benzoic acid (tolfenamic acid, 204 mg, 0.78 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 173 mg, 0.9 mmol) were dissolved in dichloromethane (15 mL) and stirred at room temperature for 18 hours.
- dichloromethane 15 mL
- N-methyl-1-((trans)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (olacitinib , 168 mg, 0.5 mmol), 4-dimethylaminopyridine (DMAP, 61 mg, 0.5 mmol), 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3 - Acetic acid (indomethacin, 233 mg, 0.65 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 144 mg, 0.75 mmol) dissolved in dichloromethane (15 mL) and stirred at room temperature for 18 hours.
- DMAP 4-dimethylaminopyridine
- EDCI 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- N-methyl-1-((trans)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (olacitinib , 168 mg, 0.5 mmol), 4-dimethylaminopyridine (DMAP, 61 mg, 0.5 mmol), 2-((2,3-dimethylphenyl)amino)benzoic acid (mefenamic acid, 157 mg, 0.65 mmol) ) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 144 mg, 0.75 mmol) were dissolved in dichloromethane (15 mL), and stirred at room temperature for 7 hours.
- dichloromethane 15 mL
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- N-methyl-1-((trans)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (olacitinib , 168 mg, 0.5 mmol), 4-dimethylaminopyridine (DMAP, 61 mg, 0.5 mmol), 2-[4-(2-oxocyclopentan-1-ylmethyl)phenyl]propionic acid (Loso Lofenac, 160 mg, 0.65 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 144 mg, 0.75 mmol) were dissolved in dichloromethane (15 mL) , stirred at room temperature for 18 hours.
- dichloromethane 15 mL
- N-methyl-1-((trans)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (olacitinib , 168 mg, 0.5 mmol), 4-dimethylaminopyridine (DMAP, 61 mg, 0.5 mmol), N-Boc-L-phenylglycine (163 mg, 0.65 mmol) and 1-(3-dimethylaminopropyl)- 3-Ethylcarbodiimide hydrochloride (EDCI, 144 mg, 0.75 mmol) was dissolved in dichloromethane (15 mL) and stirred at room temperature for 18 hours.
- DMAP 4-dimethylaminopyridine
- EDCI 1-(3-dimethylaminopropyl)- 3-Ethylcarbodiimide hydrochloride
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- N-methyl-1-((trans)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (olacitinib , 168 mg, 0.5 mmol), 4-dimethylaminopyridine (DMAP, 61 mg, 0.5 mmol), 2-(4-acetylaminophenyl)acetic acid (Actali, 126 mg, 0.65 mmol) and 1-(3- Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 144 mg, 0.75 mmol) was dissolved in dichloromethane (15 mL) and stirred at room temperature for 18 hours.
- DMAP 4-dimethylaminopyridine
- Actali 126 mg, 0.65 mmol
- EDCI 1-(3- Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- Step 1 2-(1-(ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2 , Synthesis of 3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile
- trifluoroacetic acid (6.44g, 56.5mmol) was slowly added dropwise to 2-(1-(ethylsulfonyl)-3-(4-(7-((2-( Trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidine-3- base) in a solution of acetonitrile (5g, 11.3mmol) in dichloromethane (100mL). After half an hour, remove the ice water bath, raise the temperature to room temperature and continue stirring for 24 hours. At 0°C, add saturated sodium bicarbonate solution to the above reaction solution to adjust the pH to 8.
- Step 3 (4-(1-(3-(cyanomethyl)-1-(ethylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-7H- Synthesis of methyl pyrrolo[2,3-d]pyrimidin-7-yl)(S)-2-(4-isobutylphenyl)propionate
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- N-methyl-1-((trans)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (olacitinib , 168 mg, 0.5 mmol), 4-dimethylaminopyridine (DMAP, 61 mg, 0.5 mmol), 2-(3-phenoxyphenyl)propionic acid (fenoprofen, 158 mg, 0.65 mmol) and 1-( 3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 144 mg, 0.75 mmol) was dissolved in dichloromethane (15 mL) and stirred at room temperature for 18 hours.
- dichloromethane 15 mL
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- Step 1 (R)-3-cyclopentyl-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3 Synthesis of -d]pyrimidin-4-yl)-1H-pyrazol-1-yl)propionitrile
- reaction solution is diluted with dichloromethane, and washed with water and saturated saline solution.
- Step 3 (4-(1-((R)-2-cyano-1-cyclopentylethyl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d] Synthesis of pyrimidin-7-yl)methyl(S)-2-(4-isobutylphenyl)propionate
- Step 1 N-methyl-1-((trans)-4-(methyl(7-((2-(trimethylsilyl)ethoxy)methyl))-7H-pyrrolo[ Synthesis of 2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide
- N-methyl-1-((trans)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (Oclacitinib, 1687mg, 5mmol) and N,N-diisopropylethylamine (780mg, 6mmoL) were added to dichloromethane (50mL). After stirring at room temperature for half an hour, (2-( Chloromethoxy)ethyl)trimethylsilane (1g, 6mmol), continue stirring at room temperature overnight. After the reaction is completed, the reaction solution is diluted with dichloromethane, and washed with water and saturated saline solution.
- Step 3 (4-(Methyl((trans)-4-((N-methylsulfamoyl)methyl)cyclohexyl)amino)-7H-pyrrolo[2,3-d]pyrimidine- Synthesis of 7-yl)methyl(S)-2-(4-isobutylphenyl)propionate
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- N-methyl-1-((trans)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide (olacitinib , 150mg, 0.44mmol), 4-dimethylaminopyridine (DMAP, 6mg, 0.044mmol), 2-(4-isobutylphenyl)propionic acid (ibuprofen, 96mg, 0.468mmol) and 1-(3- Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 128 mg, 0.666 mmol) was dissolved in dichloromethane (6 mL) and stirred at room temperature for 16 hours.
- DMAP 4-dimethylaminopyridine
- ibuprofen 2-(4-isobutylphenyl)propionic acid
- ibuprofen 96mg, 0.468mmol
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- Isopropyl ester (DIAD, 53 mg, 0.26 mmol), keep stirring at -10°C for 20 minutes, then naturally rise to room temperature, add 3-((3R, 4R)-3-((7-(hydroxymethyl)-7H-pyrrole) Add [2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropionitrile (68 mg, 0.2 mmol) and continue stirring. And monitor the reaction by TLC. After the starting material disappeared completely (1 hour), the solvent was evaporated under reduced pressure to obtain the crude product.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
- reaction solution was diluted with methylene chloride, and washed with water and saturated saline solution.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
化合物编号 | CPD-002 | CPD-017 | CPD-027 | CPD-028 | CPD-029 |
化合物百分比 | 2 | 2 | 2 | 2 | 2 |
溶剂百分比 | 15 | 15 | 15 | 15 | 15 |
基质百分比 | 80 | 80 | 80 | 80 | 80 |
辅料百分比 | 3 | 3 | 3 | 3 | 3 |
总计(重量/重量) | 100 | 100 | 100 | 100 | 100 |
Claims (22)
- 一种抗炎化合物、或其立体异构体、互变异构体、氮氧化物、代谢物、前药、药学上可接受的盐或溶剂化物,其结构如通式(I)所示:A-Y-B (I)其中,A为具有JAK抑制活性的胺类化合物脱氢后的基团;Y为直接连接;或者-(CH 2)-O-或-(CH 2)-;B为含有羧基的羧酸类化合物B 1脱羟基形成的基团;或含羟基类化合物B 2脱氢后形成的基团;其中,所述羧酸类化合物B 1脱羟基形成基团的情况下,所述Y基团为直接连接或者-(CH 2)-O-;所述含羟基类化合物B 2脱氢形成基团的情况下,所述Y基团为-(CH 2)-。
- 如权利要求1所述的抗炎化合物、或其立体异构体、互变异构体、氮氧化物、代谢物、前药、药学上可接受的盐或溶剂化物,其结构如通式(II)所示或通式(IIa)所示:其中,R 1选自未取代或Ra取代的吡唑基或吡咯基;或者 -N(CH 3)-Cy;R 1a表示被卤素取代的C1-C6烷基胺基酰基取代和/或C1-C6烷基取代的吡咯环;Cy为未取代或被R b取代的五元或六元碳环、五元或六元含氮杂环,所述R a和R b各自独立地为含有酰基、二硫酰基、氰基、氨基或C1-C6烷基取代氨基、四元或五元或六元含氮杂环基或者被C1-C6烷基取代的所述含氮杂环基中至少一种或二种基团;优选所述R a和R b各自独立地为酰基或二硫酰基中的一种和选自氰基、氨基或C1-C6烷基取代氨基、四元或五元或六元含氮杂环基或者被C1-C6烷基取代的所述含氮杂环基中的至少一种基团,其中,所述C1-C6烷基可被卤素取代;通式(II)和通式(IIa)中的R 2均为-B,即为羧酸类化合物B 1脱除羟基形成的基团-B 1,选自R 4-Ar-R 3-CO-,其中,R 3选自C1-C6亚烷基;-NH-、R 5NH-或C1-C6烷氧基酰胺基团取代的C1-C6亚烷基;或直接连接即Ar基团直接连接-CO-;R 3优选为甲基取代或未取代的亚甲基、-C 2H 4-、或者直接连接;R 5为C1-C6亚烷基;其中,所述C1-C6亚烷基可被卤素取代(优选卤素选自氟、氯或溴中的一种或二种以上);Ar为芳环基团,优选选自苯环;萘环或芳杂环;以及被选自卤素、C1-C6烷基、C1-C6烷氧基、C1-C6酰基或C1-C6烷氧基中的一种以上基团取代的苯环、萘环或者芳杂环或芳稠杂环(这里,芳杂环优选为苯并含氮或氧杂环如苯并吡咯环);Ar更优选含氮原子的芳杂环;R 4为卤素,C1-C6烷基,C1-C6烷氧基,含C1-C6环烷酰基的C1-C6烷基,C1-C6烷酰胺基或芳稠杂环酰胺基,C1-C6碳酰氧基,卤素取代的苯甲酰基,C1-C6烷基或卤素取代或未取代的苯氧基,C1-C6烷基或卤素取代或未取代的苯基或芳稠杂环,C1-C6烷基或卤素取代或未取代的苯基胺基,或者R 4也可以没有;其中,所述C1-C6烷氧基也可以与Ar形成桥环。
- 如权利要求2所述的抗炎化合物、或其立体异构体、互变异构体、氮氧化物、代谢物、前药、药学上可接受的盐或溶剂化物,其中Cy为取代的环己基或取代的哌啶基;优选所述取代的环己基为被含有氨基和二硫酰基取代的环己基,所述取代的哌啶基为被含有酰基 或二硫酰基和-CN取代的哌啶基。
- 如权利要求1-3任一项所述的化合物、或其立体异构体、互变异构体、氮氧化物、代谢物、前药、药学上可接受的盐或溶剂化物,其中,其为胺类化合物A与羧酸类化合物B 1缩合反应得到的偶联化合物。
- 如权利要求6所述的抗炎化合物、或其立体异构体、互变异构体、氮氧化物、代谢物、前药、药学上可接受的盐或溶剂化物,其为选自托法替尼、巴瑞克替尼、奥拉替尼、乌帕替尼、鲁索替尼和迪高替尼中的一种胺类化合物A与选自布洛芬、(S)-(+)-布洛芬、萘普生、菲诺洛芬、氟比洛芬、洛索洛芬酸、酮洛芬、依托度酸、阿克他利和吲哚美辛中的一种羧酸类化合物B 1缩合反应得到的偶联化合物;优选所述胺类化合物为托法替尼、鲁索替尼和巴瑞替尼。
- 如权利要求1所述的抗炎化合物、或其立体异构体、互变异构体、氮氧化物、代谢物、前药、药学上可接受的盐或溶剂化物,其结构如通式(III)所示:其中,R 1与通式(II)中的R 1含义相同;R 1a与通式(IIa)中的R 1a含义相同;通式(III)和通式(IIIa)中的R 2’均为Y-B,B为通式(II)或(IIa)中的B 1,或者B为B 2;其中,所述基团-B 1为羧酸类化合物B 1脱羟基形成的基团,此时Y-为(CH 2)-O-;所述基团-B 2为含羟基类化合物B 2脱氢形成的基团,此时Y-为-(CH 2)-;所述基团-B 1与通式(II)或通式(IIa)中的R 2基团含义相同;所述基团-B 2为R c-CO-NH-R d,其中R c为如下结构式(a)所示的4-羟基-苯并噻嗪二氧化物-3-基团(其中苯环可被卤素或C1-C6烷基取代)或者为如下结构式(b)所示的4-羟基-Re取代噻吩并噻嗪二氧化物-3-基团,其中在噻嗪环3-位上连接-CO-NH-R d,其中,R d为噻唑、异噻唑、噁唑、异噁唑、或吡啶或者它们被C1-C6烷基或卤素取代的基团,优选为被甲基取代的噻唑、异噁唑;以及未被取代的吡啶基;R e为C1-C6烷基或卤素(优选卤素选自氟、氯或溴中的一种或二种以上),式(b)R e旁边的箭头表示其在噻吩环上的取代位置可以为任意能发生取代的碳连接的氢原子。
- 如权利要求11或12所述的抗炎化合物、或其立体异构体、互变异构体、氮氧化物、代谢物、前药、药学上可接受的盐或溶剂化物,其通过包括如下步骤的制备方法得到:2)使A-CH 2-OH化合物与B的酰氯化物或者B化合物直接反应得到;其中,所述A-CH 2-OH化合物优选通过下面的步骤1)制备:使胺类化合物A形成A-CH 2-OH化合物。
- 权利要求2-10任一项所述抗炎化合物、或其立体异构体、互变异构体、氮氧化物、代谢物、前药、药学上可接受的盐或溶剂化物的制备方法,包括如下步骤:A和B在催化剂和有机溶剂存在下发生失去水的缩合反应反应得到。
- 根据权利要求16所述的制备方法,其中,所述催化剂为EDCI(1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐)),DCC(二环己基碳二亚胺)、CDI(N,N-碳酰二咪唑)、DMTMM(4-(4,6-二甲氧基三嗪)-4-甲基吗啉盐酸盐)、HATU(2-(7-氮杂苯并三氮唑)-N,N,N′,N′-四甲基脲六氟磷酸酯)、HCTU(6-氯苯并三氮唑-1,1,3,3-四甲基脲六氟磷酸酯)、PyBOP(六氟磷酸苯并三唑-1-基-氧基三吡咯烷基磷)、NPC中的一种或二种以上;优选所述有机溶剂选自DCM(二氯甲烷)、DMF(二甲基甲酰胺)、石油醚、丙酮、氯仿、乙酸乙酯、乙腈,THF(四氢呋喃)中的一种或二种以上,更优选为二氯甲烷和/或二甲基甲酰胺;进一步优选在碱性物质存在反应,其中所述碱性物质优选选自DMAP(二甲氨基吡啶)、三乙胺、DIPEA(N,N-二异丙基乙胺)以及钠、钾、锂和铵的氢氧化物或者盐中的一种或二种以上。
- 权利要求11-15任一项所述的抗炎化合物、或其立体异构体、互变异构体、氮氧化物、代谢物、前药、药学上可接受的盐或溶剂化物的制备方法,其包括如下步骤:采用A-CH 2OH与B发生失去水缩合反应得到。
- 根据权利要求11-15任一项所述的抗炎化合物、或其立体异构体、互变异构体、氮氧化物、代谢物、前药、药学上可接受的盐或溶剂化物的制备方法,其通过包括如下步骤的制备方法得到:2)使A-CH 2-OH化合物与B的酰氯化物或者B化合物直接反应得到;其中,所述A-CH 2-OH化合物优选通过下面的步骤1)制备:使胺类化合物A形成A-CH 2-OH化合物。
- 根据权利要求19所述的制备方法,其中,步骤1)包括:a)在A中加入(2-(氯甲氧基)乙基)三甲基硅烷在催化剂和溶剂存在下生成A-CH 2O-C 2H 4-Si(CH 3) 3;和b)A-CH 2O-C 2H 4-Si(CH 3) 3在催化剂和溶剂存在下形成A-CH 2OH;步骤2)为:A-CH 2OH与B 1化合物形成的酰氯或者B 2化合物直接反应形成A-CH 2O-B;其中优选的是,步骤b)中,在TFA(三氟乙酸)作为催化剂和DCM(二氯甲烷)作为溶剂存在下反应;步骤2)中,在Et 3N(三乙胺)作为催化剂和DCM(二氯甲烷)作为溶剂的存在下A-CH 2OH与B 1化合物形成的酰氯进行反应或者在PPh3(三苯基膦)以及DIAD(偶氮二甲酸二异丙酯)作为催化剂和THF(四氢呋喃)作为溶剂存在下A-CH 2OH与B 2化合物进行反应。
- 权利要求1-15任一项所述的抗炎化合物、或其立体异构体、互变异构体、氮氧化物、代谢物、前药、药学上可接受的盐或溶剂化物其用于在制备抗炎药物制剂或药物组合物(优选外用药物组合物)中的应用。
- 一种抗炎药物制剂或药物组合物(优选外用药物组合物),其含有权利要求1-15任一项所述的抗炎化合物、或其立体异构体、互变异构体、氮氧化物、代谢物、前药、药学上可接受的盐或溶剂化物。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3224493A CA3224493A1 (en) | 2021-07-20 | 2022-07-13 | External anti-inflammatory coupling compound drug, and preparation method therefor and use thereof |
AU2022313345A AU2022313345A1 (en) | 2021-07-20 | 2022-07-13 | External anti-inflammatory coupling compound drug, and preparation method therefor and use thereof |
EP22845210.8A EP4357346A1 (en) | 2021-07-20 | 2022-07-13 | External anti-inflammatory coupling compound drug, and preparation method therefor and use thereof |
KR1020247002770A KR20240027732A (ko) | 2021-07-20 | 2022-07-13 | 외용 항염증 결합 화합물 약물 및 그 제조 방법과 응용 |
IL309840A IL309840A (en) | 2021-07-20 | 2022-07-13 | An external antidialectic coupling compound drug, and a method of preparation therefor and use thereof |
CN202280035110.4A CN117355527B (zh) | 2021-07-20 | 2022-07-13 | 一种消炎偶联化合物药物及其制法和应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110834326.4 | 2021-07-20 | ||
CN202110834326 | 2021-07-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023001045A1 WO2023001045A1 (zh) | 2023-01-26 |
WO2023001045A9 true WO2023001045A9 (zh) | 2023-10-26 |
Family
ID=84978879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/105503 WO2023001045A1 (zh) | 2021-07-20 | 2022-07-13 | 一种外用消炎偶联化合物药物及其制法和应用 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4357346A1 (zh) |
KR (1) | KR20240027732A (zh) |
AU (1) | AU2022313345A1 (zh) |
CA (1) | CA3224493A1 (zh) |
IL (1) | IL309840A (zh) |
WO (1) | WO2023001045A1 (zh) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190231A1 (ar) * | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
CN108699063B (zh) * | 2015-12-31 | 2020-06-26 | 正大天晴药业集团股份有限公司 | 一种芦可替尼的合成工艺 |
WO2020176859A1 (en) * | 2019-02-28 | 2020-09-03 | Puretech Lyt, Inc. | Lipid prodrugs of jak inhibitors and uses thereof |
CA3131977C (en) * | 2019-03-22 | 2022-04-26 | Integrated Nanotherapeutics Inc. | Lipid conjugate prepared from scaffold moiety |
CN110734428A (zh) * | 2019-10-24 | 2020-01-31 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
CN117838875A (zh) * | 2020-07-15 | 2024-04-09 | 上海椿安生物医药科技有限公司 | 用于局部递送治疗剂的药物递送系统以及其用途 |
-
2022
- 2022-07-13 WO PCT/CN2022/105503 patent/WO2023001045A1/zh active Application Filing
- 2022-07-13 EP EP22845210.8A patent/EP4357346A1/en active Pending
- 2022-07-13 CA CA3224493A patent/CA3224493A1/en active Pending
- 2022-07-13 KR KR1020247002770A patent/KR20240027732A/ko active Search and Examination
- 2022-07-13 AU AU2022313345A patent/AU2022313345A1/en active Pending
- 2022-07-13 IL IL309840A patent/IL309840A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2022313345A1 (en) | 2024-02-01 |
EP4357346A1 (en) | 2024-04-24 |
KR20240027732A (ko) | 2024-03-04 |
IL309840A (en) | 2024-02-01 |
CA3224493A1 (en) | 2023-01-26 |
CN117355527A (zh) | 2024-01-05 |
WO2023001045A1 (zh) | 2023-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112312904A (zh) | 螺环化合物 | |
JP2020519596A (ja) | Irak−4阻害剤として有用なチエノピリジンおよびベンゾチオフェン | |
KR20060015294A (ko) | 피라졸로-퀴나졸린 유도체, 그의 제조 방법 및 상기유도체의 키나제 저해제로서의 용도 | |
KR20130133905A (ko) | 트로포미오신-관련 키나제의 억제제인 피롤로[2,3-d]피리미딘 유도체 | |
NZ515281A (en) | New dihydro[1,2,4]triazole derivatives useful as protein kinase C inhibitors | |
EA028175B1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
JP7148709B2 (ja) | バニン阻害剤としてのヘテロ芳香族化合物 | |
CN111801100B (zh) | 用于治疗和预防肝癌的7-取代的磺亚氨酰基嘌呤酮化合物和衍生物 | |
JP2018512062A (ja) | Tnf阻害剤として有用なヘテロ環式化合物 | |
JP2002105081A (ja) | 新規チオフェンニ環化合物 | |
AU2021219097A1 (en) | P2X3 modulators | |
AU2020371836A1 (en) | Pyrrole amide compound and use thereof | |
WO2018214796A1 (zh) | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 | |
ES2788660T3 (es) | Derivados de 2,3-dihidro-1h-inden-1-ona como antagonistas de receptores huérfanos relacionados con el ácido retinoico gamma (ROR gamma) para el tratamiento de la esclerosis múltiple | |
AU2022240688A1 (en) | Furan fused ring-substituted glutarimide compound | |
JP5874989B2 (ja) | 抗がん剤 | |
WO2016184312A1 (zh) | 羟基嘌呤类化合物及其应用 | |
JP6935102B2 (ja) | 選択的抗癌化合物 | |
JP3537446B2 (ja) | 三環性ベンゾアゼピン化合物 | |
CN109641909A (zh) | 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用 | |
WO2023001045A9 (zh) | 一种外用消炎偶联化合物药物及其制法和应用 | |
WO2023081759A1 (en) | Bifunctional pi3k-alpha inhibitors and uses thereof | |
WO2001078780A1 (fr) | Agents preventifs/remedes pour la maladie d'alzheimer | |
CN117355527B (zh) | 一种消炎偶联化合物药物及其制法和应用 | |
CN116600808A (zh) | 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22845210 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280035110.4 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3224493 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 309840 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022313345 Country of ref document: AU Ref document number: 2022845210 Country of ref document: EP Ref document number: 807412 Country of ref document: NZ Ref document number: AU2022313345 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20247002770 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020247002770 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2022313345 Country of ref document: AU Date of ref document: 20220713 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2022845210 Country of ref document: EP Effective date: 20240116 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2024104095 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |